Somerset Medical Center, established in 1899, has long served as a community cornerstone for general health and science information, reflecting a heritage of broad public health education. This legacy encompasses foundational knowledge about disease prevention, environmental factors, and wellness—topics that naturally extend into more specialized areas of occupational health. As industrial processes expanded throughout the twentieth century, the general health context provided by institutions like Somerset Medical Center began to intersect with emerging concerns about workplace exposures. The transition from broad health education to specific occupational risk factors is a logical progression, as the same principles of understanding environmental influences on health apply to both community and workplace settings. Benzene, a widely used industrial solvent, represents a point where general health awareness meets occupational exposure concern. While the general health context has historically addressed chemical safety in broad terms, the focus now shifts to the specific risks faced by workers in industries where benzene is prevalent.
Benzene is a well-established myelotoxin and a recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is acknowledged as a myelotoxin that is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Furthermore, a meta-analysis of 25 studies found an elevated risk of AML in children exposed to benzene, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).
The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, fever, and easy bruising or bleeding, due to anemia, neutropenia, and thrombocytopenia. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts, along with cytogenetic and molecular testing to classify subtypes. Benzene-induced AML often shares these features but may be preceded by myelodysplastic syndromes (MDS), a preleukemic condition. The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by MDS and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).
Mechanistic pathways linking benzene to AML involve several biological processes. Possible mechanisms of benzene initiation of hematological tumors have been identified, including a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene metabolites, such as hydroquinone and benzoquinone, can cause DNA damage, chromosomal aberrations, and epigenetic changes, including altered gene expression. These effects can lead to clonal expansion of hematopoietic stem cells with mutations, ultimately resulting in AML. The epigenetic effects of benzene in hematologic neoplasms include altered gene expression, which may contribute to leukemogenesis (https://pubmed.ncbi.nlm.nih.gov/34069279/).
Risk considerations for affected patients include the adequacy of warnings regarding benzene and AML. Occupational exposure limits have been established in many countries, but historical exposures often exceeded current standards. The latency period between benzene exposure and development of AML can range from several years to decades, depending on the intensity and duration of exposure. In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). This underscores the importance of ongoing surveillance and risk communication for workers in industries where benzene is used, such as chemical manufacturing, petroleum refining, and rubber production.
Causation-related considerations for affected patients involve establishing a temporal relationship between exposure and disease. The timeline between exposure and documented harm is critical; AML typically develops after chronic exposure over months to years, though acute high-level exposure may also increase risk. The key event-informed risk models for benzene-induced AML suggest that incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). For patients with AML and a history of benzene exposure, medical evaluation should include a detailed occupational and environmental history to assess potential causation. Legal and compensation frameworks may require evidence of significant exposure, typically at levels above occupational limits, and a plausible latency period. In summary, benzene is a confirmed cause of AML, with evidence from occupational cohort studies, meta-analyses, and mechanistic research. The risk is dose-dependent, with higher exposures associated with greater risk. Adequate warnings and exposure controls are essential to prevent benzene-induced AML. For affected patients, understanding the exposure-disease relationship is important for clinical management and potential legal recourse.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Yes, benzene is a confirmed cause of acute myeloid leukemia (AML). Extensive evidence from occupational cohort studies, meta-analyses, and mechanistic research demonstrates a causal relationship between benzene exposure and AML. The risk is dose-dependent, with higher exposures associated with greater risk.
Symptoms of AML include fatigue, pallor, fever, easy bruising or bleeding due to bone marrow failure. Benzene-induced AML may be preceded by myelodysplastic syndromes. Diagnosis requires bone marrow biopsy showing at least 20% blasts.
The latency period between benzene exposure and development of AML can range from several years to decades, depending on the intensity and duration of exposure. Chronic exposure over months to years is typical, though acute high-level exposure may also increase risk.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.